Skip to content
    OFIX
    Earnings call· Jun 2026(Q2 FY26)

    Orthofix Medical Q2 FY26 earnings call OFIX

    Aug 5, 2026 Source

    Executive summary

    Orthofix Q2 FY26 — Strong Operational Progress Despite Distributor Headwinds

    Orthofix demonstrated tangible operational progress in Q2 FY26, achieving 5% pro forma constant currency net sales growth driven by strong performance in Global Limb Reconstruction and Spine Fixation. While the restoration of Medicare reimbursement and stabilization in Biologics are positive indicators, the company faces ongoing challenges with smaller U.S. spine distributors, leading to a more conservative full-year outlook. Management remains focused on improving commercial productivity and disciplined capital allocation for long-term value creation.

    Highlights

    5

    • Achieved 5% pro forma constant currency net sales growth over prior year.

    • Global Limb Reconstruction net sales grew 11% on a constant currency basis.

    • Global Spine Fixation net sales grew 10% on a constant currency basis.

    • Biologics net sales were approximately flat year-over-year, a significant improvement from prior contractions.

    • Medicare reimbursement for bone growth stimulators was restored to its prior level, retroactive to May 18, 2026.

    Concerns

    4

    • U.S. spine fixation net sales grew only 3% in the quarter due to ongoing softness among smaller distributors.

    • Profitability was impacted by unfavorable geographic mix and credit losses in certain international markets.

    • The European distributor arrangement is expected to create an approximately $22 million net sales headwind in 2027.

    • A temporary free cash flow timing headwind is projected for 2026 due to the European distributor arrangement.

    Guidance & targets

    6
    CategoryTargetConfidence
    Full-year 2026 Net Sales
    $845 million to $855 million
    high materiality
    High
    Full-year 2026 Adjusted EBITDA
    $95 million to $98 million
    high materiality
    High
    Q3 Net Sales
    generally consistent with Q2
    medium materiality
    Medium
    Q4 Net Sales
    sequential growth
    medium materiality
    Medium
    European Distributor Arrangement Net Sales Benefit
    approximately $15 million
    medium materiality
    High
    European Distributor Arrangement Net Sales Headwind
    approximately $22 million
    high materiality
    High

    Segment performance

    3
    SegmentRevenueYoYQoQMargin
    Global Spinal Implants, Biologics and Enabling Technologies
    Increase versus prior year period, led by spine fixation, benefiting from continued international momentum and timing of international distributor orders.
    		$109 million4%——
    Therapeutic Solutions
    Up year-over-year despite temporary reimbursement pressure, reinforcing resilient underlying demand. Expected to contribute more favorably in the second half with Medicare reimbursement restored.
    		$64.2 million3%——
    Global Limb Reconstruction
    Increase driven by strong international demand and continued adoption of key product families. U.S. growth was more modest, with second half assumptions reflecting greater commercial productivity.
    Key product families adoption: TrueLok Elevate, FITBONE
    		$37.7 million11%——

    Operational metrics

    6
    Non-GAAP Adjusted Gross Margin
    71.7%
    Q2 FY26

    Reflecting an unfavorable geography mix during the quarter.

    Adjusted EBITDA
    $20.1 million
    Q2 FY26

    Profitability was impacted by geographic mix and credit losses in certain international markets and continued investment in key launches partially offset by ongoing cost optimization initiatives.

    Total Cash
    $104.4 million
    Q2 FY26

    Ended the quarter with $104.4 million in total cash, including restricted cash, providing flexibility for operating priorities and strategic investments.

    Company-wide Net Sales Growth
    5%YoY
    Q2 FY26

    Delivered 5% pro forma constant currency net sales growth over prior year.

    Medicare Reimbursement for Bone Growth Stimulators
    restored to prior level
    Q2 FY26

    CMS restored medical reimbursement for bone growth stimulator to its prior level, following stakeholder feedback, including concerns we raised. This decision removes a meaningful headwind.

    Top Distributors Contribution to Spine Fixation Sales
    80%
    Q2 FY26

    Our top 30 distributors represent approximately 80% of our spine fixation sales continued to perform well.

    Industry KPIs

    5
    MetricValueDetails
    New product launch rampFull market launch
    FCF conversion leverage guidance5%%
    Segment franchise organic growth11%%
    Indicated addressable patient populationDiabetic foot ulcer
    Pivotal trial clinical evidence milestonesIDE submitted

    Product announcements

    2
    ProductTypeDetails
    Virata minimally invasive systemmilestone
    Access STIM 2.0launch

    Deals & partnerships

    1
    European distributorStrategic arrangement to support continued market access for spine products in Europe without pursuing full MDR compliance.

    This arrangement allows Orthofix to preserve a targeted opportunity in Europe while maintaining disciplined investment priorities. It creates a temporary free cash flow timing headwind in 2026.

    Risks & headwinds

    4
    Ongoing softness among smaller U.S. spine distributorsBalance of FY26

    U.S. spine fixation net sales up 3% in Q2, below expectations. Expected to continue through the balance of the year.

    Mitigation: Actively evaluating where to generate the best long-term returns, being disciplined about resource investment, and choosing to consolidate or exit relationships not delivering sustainable growth.

    Profitability impact from geographic mix and credit lossesQ2 FY26

    Non-GAAP adjusted gross margin was 71.7%, impacted by unfavorable geography mix. Adjusted EBITDA was $20.1 million, impacted by geographic mix and credit losses in certain international markets.

    Mitigation: Ongoing cost optimization initiatives and resource alignment are expected to support full-year profitability outlook.

    Net sales headwind from European distributor arrangement in 2027FY27

    Approximately $22 million net sales headwind.

    Mitigation: The arrangement allows preservation of a targeted opportunity in Europe while MDR requirements are completed, aligning with disciplined investment priorities.

    Temporary free cash flow timing headwind in 2026FY26

    Some cash receipts projected in 2027, while inventory-related cash outflows occur in 2026.

    Mitigation: This timing dynamic does not change the view of the underlying cash-generating potential of the business or the quality of earnings.

    What to watch in Q3 FY26

    5

    Small U.S. spine distributor performance

    Balance of FY26 / Next quarter
    CurrentSoftness, below expectations, impacting U.S. spine fixation growth (up 3% in Q2).
    TargetImproved productivity or successful consolidation/exit of underperforming relationships.

    Why it matters

    This impacts overall U.S. spine fixation growth and commercial productivity, central to the company's focus on quality revenue.

    those positives are offset by ongoing softness among smaller U.S. spine distributors performance remains below our expectations and is reflected in our outlook for the balance of the year.

    Q&A highlights

    5

    Why was the guidance increase not as significant as expected given the CMS changes, and what other factors are influencing the updated outlook?

    The updated outlook reflects a combination of positive factors like the $12 million benefit from Medicare reimbursement restoration and $15 million from the European distributor arrangement, offset by ongoing softness among smaller U.S. spine distributors. The company aims for transparency regarding progress and execution risks.

    “So first, on the positive side, we have the restoration of the Medicare reimbursement, which is approximately a $12 million benefit as well as the European distributor arrangement, which is expected to contribute approximately $15 million of incremental net sales in 2026.”

    asked by Caitlin Cronin · answered by Julie Andrews

    2 min read6 chapters

    Detailed Narrative

    01

    Spine Business Performance and Distributor Strategy

    Global Spine Fixation net sales grew 10% on a constant currency basis, with U.S. spine fixation up 3%. The top 30 distributors, representing 80% of sales, performed well, but smaller distributors showed steeper declines. Management is actively evaluating these relationships to consolidate or exit those not delivering sustainable growth, prioritizing profitable growth and strong returns. Challenges with smaller distributors are expected to continue through the balance of the year.

    02

    Biologics Business Turnaround

    Biologics net sales were approximately flat year-over-year, a significant improvement from double-digit contractions in 2025. This marks the second consecutive quarter of improved performance. The company is focusing on converting this constructive trajectory into durable growth through stronger account engagement, higher utilization, and targeted commercial focus on key products like Osteo bioactive synthetic bone graft. Investments are also being made in clinical evidence generation for Osteocove and Virtus, and a product registry for STEM.

    03

    Therapeutic Solutions Resilience and Reimbursement

    Therapeutic Solutions delivered 3% year-over-year net sales growth despite temporary Medicare reimbursement pressure during part of Q2. The Centers for Medicare & Medicaid Services (CMS) restored medical reimbursement for bone growth stimulators to its prior level, retroactive to May 18, 2026, removing a meaningful headwind. The company plans to continue investing in elevating the patient and physician experience, including the launch of Access STIM 2.0, a redesigned bone growth therapy device.

    04

    Global Limb Reconstruction Momentum and Future Opportunities

    Global Limb Reconstruction demonstrated solid performance, with net sales growing 11% on a constant currency basis, driven by strong international momentum and products like TrueLok Elevate and FITBONE. U.S. growth was below expectations due to commercial infrastructure needs. The company is improving distributor productivity and expanding market development. They also see opportunities in adjacent areas like diabetic foot ulcer, where an IDE has been submitted to the FDA to support potential expanded indications.

    05

    European MDR Strategy and Financial Impact

    Orthofix has a strategic arrangement with a European distributor for spine products to preserve market access without pursuing full MDR compliance for the entire portfolio. This arrangement is expected to contribute approximately $15 million of incremental net sales in 2026, mostly in Q4, but will create an approximately $22 million net sales headwind in 2027 while MDR requirements are completed. This also creates a temporary free cash flow timing headwind in 2026.

    06

    Updated Full-Year Outlook and Strategic Priorities

    The company updated its full-year 2026 net sales guidance to $845 million to $855 million and adjusted EBITDA guidance to $95 million to $98 million. This outlook reflects restored Medicare reimbursement, the European distributor arrangement, and stabilization in Biologics, offset by ongoing softness in smaller U.S. spine distributors. Management remains focused on improving commercial productivity, advancing differentiated innovation, and generating clinical evidence to drive durable, profitable growth and cash generation.

    AI-generated summary of the company’s earnings call. Not investment advice.